Polymorphism at position -308 of the tumour factor α gene and rheumatoid arthritis pharmacogenetics

Annals of the Rheumatic Diseases

Volumn 64, Issue 5, 2005, Pages 793-794

  Fonseca, J E ^a,b   Carvalho, T ^b   Cruz, M ^a   Nero, P ^a   Sobral, M ^b   Mourao A F ^b   Cavaleiro, J ^b   Ligeiro, D ^c   Abreu, I ^d   Carmo Fonseca, M ^b   Branco, J C ^a  

^a HOSPITAL EGAS MONIZ   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c Ministerio da Saude Portuguese   (Portugal)

^d UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DAS28 SCORE; DISEASE ACTIVITY; DISEASE DURATION; DNA EXTRACTION; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; ONSET AGE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TNF ALPHA GENE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20244363493     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.028167     Document Type: Article

References (9)

1. Fabris M, Di Poi E, Sacco S, Damante G, Sinigaglia L, Ferraccioli GI. Tumor necrosis alpha gene polymorphism in rheumatoid arthritis patients treated with anti-TNF alpha agents: preliminary results. Reumatismo 2002;54:19-26.
2. Padyukov L, Lampa J, Heimbürger M, Ernestam S, Cederholm T, Lundkvist I, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
3. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position-308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-52.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
5. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, Van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid artritis. Arthritis Rheum 1995;38:44-8.
6. Consensus GEAR/SPR para utilização de DMARD biológicos. Acta Reum Port 2003;28:187-9.
7. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
8. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
9. Grove J, Daily AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steathepatitis. Hepatology 1997;26:143-5.